Novavax’s updated COVID-19 vaccine receives emergency use authorization in the Republic of Korea; the EU, US and the World Health Organization previously authorized the vaccine for use

Sample article from our Government & Public Policy

November 29, 2023 (press release) –

Novavax’s partner, SK bioscience,today announced that Novavax’s updated COVID-19 vaccine (NVX-CoV2601) has received Emergency Use Authorization from the Ministry of Food and Drug Safety in the Republic of Korea.Doses are available in market for use this vaccination season.InSouth Korea, SK bioscience and Novavax have a licensing agreement where SK bioscience has exclusive commercial rights to Novavax’s updated COVID-19 vaccine. 

Novavax’s updated COVID-19 vaccine is also authorized in the U.S.,the European Union and by the World Health Organization,and is under review in other markets. 

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Chelsey Quick
Chelsey Quick
- VP Client Success -

We offer built-to-order government & public policy coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.